CR10699A - Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt - Google Patents
Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wntInfo
- Publication number
- CR10699A CR10699A CR10699A CR10699A CR10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A CR 10699 A CR10699 A CR 10699A
- Authority
- CR
- Costa Rica
- Prior art keywords
- wnt
- diagnosis
- treatment
- antagonists
- disorders
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82506306P | 2006-09-08 | 2006-09-08 | |
US95117507P | 2007-07-20 | 2007-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10699A true CR10699A (es) | 2009-07-10 |
Family
ID=39092004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10699A CR10699A (es) | 2006-09-08 | 2009-03-31 | Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt |
Country Status (19)
Country | Link |
---|---|
US (5) | US7947277B2 (es) |
EP (1) | EP2061495A2 (es) |
JP (1) | JP2010504081A (es) |
KR (1) | KR20090060334A (es) |
AR (1) | AR062709A1 (es) |
AU (1) | AU2007292242A1 (es) |
BR (1) | BRPI0714751A2 (es) |
CA (1) | CA2662041A1 (es) |
CL (1) | CL2007002609A1 (es) |
CR (1) | CR10699A (es) |
IL (1) | IL197240A0 (es) |
MA (1) | MA31135B1 (es) |
MX (1) | MX2009002522A (es) |
NO (1) | NO20091413L (es) |
PE (3) | PE20120806A1 (es) |
RU (1) | RU2009113023A (es) |
SG (2) | SG174101A1 (es) |
TW (1) | TW200819463A (es) |
WO (1) | WO2008031009A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1961065A4 (en) | 2005-10-31 | 2009-11-11 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
US7723477B2 (en) * | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
JP2009065938A (ja) * | 2007-09-14 | 2009-04-02 | Matsumoto Shika Univ | タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法 |
WO2009074637A1 (en) * | 2007-12-13 | 2009-06-18 | Merck Serono S.A. | Sarp-1 fusion proteins and uses thereof |
EP2274622B1 (en) | 2008-04-30 | 2014-10-08 | The Governing Council of the University of Toronto | Use of sfrp-3 in the assessment of heart failure |
ES2334092B1 (es) * | 2008-07-02 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Agentes antiangiogenicos. |
AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
EP2343080B1 (en) * | 2008-09-30 | 2017-11-08 | Kyowa Hakko Kirin Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN AND Fc PROTEIN |
WO2010124188A1 (en) | 2009-04-23 | 2010-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
US20110189097A1 (en) * | 2009-11-09 | 2011-08-04 | Dritan Agalliu | Use of WNT inhibitor to inhibit angiogenesis in the CNS |
TWI535445B (zh) * | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
EP2585098B1 (en) | 2010-06-28 | 2014-08-27 | Five Prime Therapeutics, Inc. | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders |
UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
WO2012068299A2 (en) | 2010-11-16 | 2012-05-24 | University Of Southern California | Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells |
SG189271A1 (en) | 2010-10-20 | 2013-05-31 | Genentech Inc | Methods and compositions for modulating the wnt pathway |
CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
CA2839755A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
US9428560B2 (en) | 2011-06-21 | 2016-08-30 | Kyowa Hakko Kirin Co., Ltd | Protein comprising truncated form of extracellular region protein of Frizzled 2, and pharmaceutical composition for treating bone diseases which comprises said protein |
US8802097B2 (en) | 2011-07-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Anti-RSPO1 antibodies |
US20130216546A1 (en) * | 2012-01-10 | 2013-08-22 | Ngm Biopharmaceuticals, Inc. | Methods of Treating Glucose Metabolism Disorders |
AU2013216753B2 (en) | 2012-02-11 | 2017-09-21 | Genentech, Inc. | R-spondin translocations and methods using the same |
CN104114574B (zh) * | 2012-02-20 | 2018-08-24 | 瑞典孤儿比奥维特鲁姆有限公司 | 结合人补体c5的多肽 |
AU2013334790A1 (en) * | 2012-10-23 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using Wnt pathway-binding agents |
US9957330B2 (en) * | 2012-12-19 | 2018-05-01 | Affibody Ab | Polypeptides |
EP2950885B1 (en) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
WO2015084808A1 (en) | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
US9914774B2 (en) | 2014-07-11 | 2018-03-13 | Genentech, Inc. | Notch pathway inhibition |
KR101572606B1 (ko) * | 2014-11-24 | 2015-11-27 | 강원대학교산학협력단 | Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물 |
WO2016126054A1 (ko) | 2015-02-04 | 2016-08-11 | (주)메드팩토 | 변형된 dkk2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 이를 이용한 방법 |
US10913786B2 (en) * | 2016-03-21 | 2021-02-09 | Children's Medical Center Corporation | Compositions and methods for inhibiting Wnt signaling |
CN108310366A (zh) * | 2017-01-15 | 2018-07-24 | 复旦大学附属华山医院 | 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途 |
CA3161617A1 (en) * | 2019-11-18 | 2021-05-27 | The Regents Of The University Of California | Anti-ror-2 antibodies and methods of use |
JP2023503615A (ja) * | 2019-11-26 | 2023-01-31 | シーダーズ-サイナイ メディカル センター | 循環からミトコンドリアdna又はゲノムdnaを枯渇させることにより疾患及び症状を治療する組成物及び方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039357A1 (en) | 1996-04-12 | 1997-10-23 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt RECEPTOR COMPOSITIONS AND METHODS |
DK0932678T4 (da) | 1996-09-24 | 2010-07-12 | Genentech Inc | En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåder til anvendelse deraf |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
WO2001098354A2 (en) | 2000-06-21 | 2001-12-27 | Incyte Genomics, Inc. | Human receptors |
US7413873B2 (en) | 2001-01-30 | 2008-08-19 | The Regents Of The University Of California | Method of detection and treatment of colon cancer |
AU2002308557A1 (en) | 2001-05-01 | 2002-11-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
US7713526B2 (en) | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
WO2003004045A2 (en) | 2001-07-05 | 2003-01-16 | Xenon Genetics, Inc. | Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors |
AU2002337657A1 (en) | 2001-07-25 | 2003-02-17 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
US20040247593A1 (en) | 2002-10-04 | 2004-12-09 | Regents Of The University Of California, | Methods for treating cancer by inhibiting Wnt signaling |
CA2507581A1 (en) * | 2002-12-06 | 2004-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Protection of stem cells from cytotoxic agents by modulation of .beta.-catenin signaling pathways |
US7803783B2 (en) | 2002-12-06 | 2010-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Use of WNT inhibitors to augment therapeutic index of chemotherapy |
US20050096263A1 (en) | 2003-10-30 | 2005-05-05 | Keay Susan K. | Novel antiproliferative factor and methods of use |
WO2006036175A2 (en) | 2004-09-21 | 2006-04-06 | Rhode Island Hospital, A Lifespan-Partner | Wnt proteins and detection and treatment of cancer |
US7867705B2 (en) | 2004-09-21 | 2011-01-11 | Rhode Island Hospital, A Lifespan-Partner | Frizzled proteins and detection and treatment of cancer |
JP5025475B2 (ja) | 2004-09-21 | 2012-09-12 | ロード アイランド ホスピタル エー ライフスパン−パートナー | Wntタンパク質ならびに癌の検出および治療の方法 |
WO2006055635A2 (en) | 2004-11-15 | 2006-05-26 | Mount Sinai School Of Medicine Of New York University | Compositions and methods for altering wnt autocrine signaling |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
-
2007
- 2007-09-07 CA CA002662041A patent/CA2662041A1/en not_active Abandoned
- 2007-09-07 AR ARP070103967A patent/AR062709A1/es not_active Application Discontinuation
- 2007-09-07 BR BRPI0714751-1A2A patent/BRPI0714751A2/pt not_active IP Right Cessation
- 2007-09-07 EP EP07814736A patent/EP2061495A2/en not_active Ceased
- 2007-09-07 RU RU2009113023/15A patent/RU2009113023A/ru not_active Application Discontinuation
- 2007-09-07 SG SG2011061439A patent/SG174101A1/en unknown
- 2007-09-07 PE PE2011001828A patent/PE20120806A1/es not_active Application Discontinuation
- 2007-09-07 PE PE2007001209A patent/PE20081217A1/es not_active Application Discontinuation
- 2007-09-07 JP JP2009527577A patent/JP2010504081A/ja active Pending
- 2007-09-07 US US11/851,596 patent/US7947277B2/en not_active Expired - Fee Related
- 2007-09-07 AU AU2007292242A patent/AU2007292242A1/en not_active Abandoned
- 2007-09-07 MX MX2009002522A patent/MX2009002522A/es unknown
- 2007-09-07 TW TW096133617A patent/TW200819463A/zh unknown
- 2007-09-07 SG SG2011061421A patent/SG174100A1/en unknown
- 2007-09-07 WO PCT/US2007/077845 patent/WO2008031009A2/en active Application Filing
- 2007-09-07 PE PE2011001829A patent/PE20120807A1/es not_active Application Discontinuation
- 2007-09-07 CL CL200702609A patent/CL2007002609A1/es unknown
- 2007-09-07 KR KR1020097007144A patent/KR20090060334A/ko not_active Application Discontinuation
-
2009
- 2009-02-25 IL IL197240A patent/IL197240A0/en unknown
- 2009-03-31 CR CR10699A patent/CR10699A/es unknown
- 2009-04-06 MA MA31763A patent/MA31135B1/fr unknown
- 2009-04-07 NO NO20091413A patent/NO20091413L/no not_active Application Discontinuation
-
2010
- 2010-06-29 US US12/826,194 patent/US20100266593A1/en not_active Abandoned
-
2011
- 2011-05-23 US US13/113,211 patent/US20110311534A1/en not_active Abandoned
-
2012
- 2012-02-07 US US13/367,760 patent/US20120141481A1/en not_active Abandoned
-
2016
- 2016-12-20 US US15/385,528 patent/US20170349639A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110311534A1 (en) | 2011-12-22 |
AR062709A1 (es) | 2008-11-26 |
PE20120806A1 (es) | 2012-07-25 |
US20080299136A1 (en) | 2008-12-04 |
WO2008031009A3 (en) | 2009-07-02 |
KR20090060334A (ko) | 2009-06-11 |
US20170349639A1 (en) | 2017-12-07 |
NO20091413L (no) | 2009-06-08 |
IL197240A0 (en) | 2011-08-01 |
US20100266593A1 (en) | 2010-10-21 |
WO2008031009A2 (en) | 2008-03-13 |
RU2009113023A (ru) | 2010-10-20 |
BRPI0714751A2 (pt) | 2014-06-24 |
MA31135B1 (fr) | 2010-02-01 |
EP2061495A2 (en) | 2009-05-27 |
SG174101A1 (en) | 2011-09-29 |
TW200819463A (en) | 2008-05-01 |
CA2662041A1 (en) | 2008-03-13 |
US7947277B2 (en) | 2011-05-24 |
CL2007002609A1 (es) | 2008-04-18 |
PE20081217A1 (es) | 2008-09-24 |
MX2009002522A (es) | 2009-06-19 |
SG174100A1 (en) | 2011-09-29 |
US20120141481A1 (en) | 2012-06-07 |
AU2007292242A1 (en) | 2008-03-13 |
PE20120807A1 (es) | 2012-07-26 |
JP2010504081A (ja) | 2010-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10699A (es) | Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt | |
HK1142777A1 (en) | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma lingo-1 trkb | |
HK1146596A1 (en) | Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4 | |
CL2007002327A1 (es) | Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc. | |
ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
BRPI1005292A2 (pt) | composição de decapagem e uso da composição | |
BRPI0815204A2 (pt) | Dispositivo de administração fecal e utilização do dispositivo | |
BRPI0817298A2 (pt) | Combinações de substâncias ativas com propriedades inseticidas e acaricidas | |
CR10725A (es) | Compuestos de pirazolina y su uso y composiones farmaceuticas | |
BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
DE602006003491D1 (de) | Beobachtungsvorrichtung und Beobachtungsverfahren | |
BRPI0913822A2 (pt) | forma farmacêutica oral e uso da forma farmacêutica | |
ME02343B (me) | Derivati alfa-aminoamida korisni u liječenju kognitivnih poremećaja | |
BRPI0816835A2 (pt) | dispositivo de pulverização e método de uso do mesmo | |
BRPI0919903A2 (pt) | dispositivo de mobilização corporal e utilização do dispositivo | |
BRPI0719345A2 (pt) | Di-hidroimidazóis substituídos e seu uso no tratamento de tumores. | |
ZA200902419B (en) | Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases | |
CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
BRPI0810475A2 (pt) | uso de dimiracetam no tratamento de dor crônica | |
DK2124997T3 (da) | Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt | |
CR10430A (es) | Aminothiazoles and their uses | |
CL2007002769A1 (es) | Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes. | |
BRPI0818121A2 (pt) | diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização | |
DK3156057T3 (da) | Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis | |
BRPI0817483A2 (pt) | uso de n-fenilamidas de ácido 2-sulfonilaminobenzoico substituídas por sulfonila no tratamento da dor |